What are the qualitative experiences of people affected by kidney failure receiving haemodialysis?

Abstract

Background: People affected by kidney failure receiving haemodialysis experience complexity within their health condition unlike any other chronic illness or condition.Kidney failure impacts the individual in all areas of their life including relationships and activities of daily living.Objective: To conduct a meta-aggregation of studies about the lived experiences of people with kidney failure receiving haemodialysis.Design: Using PRISMA Guidelines, six databases (CINAHL, ClinicalTrials.gov, Cochrane Library, MEDLINE, PsycINFO, and Scopus) were comprehensively searched using keywords and subject headings from January 1990 to October 2021. Articles were assessed according to prespecified eligibility criteria. Data extraction and quality appraisal was conducted. A meta-aggregation of qualitative findings was conducted using the Joanna Briggs Institute methodology for meta-aggregation.Results: Of the 9409 articles screened, 55 studies were included. This represented a total of 188 findings across 45 categories representing a range of unmet supportive care needs. The meta-aggregation identified 11 synthesised findings broadly related to psychological/emotional needs, physical needs, social needs, interpersonal/ intimacy needs, patient-clinician communication needs, family related needs, health system/information needs, spiritual needs, daily living needs, practical needs and daily living needs.Conclusions: This meta-aggregation has identified that people affected by kidney failure can experience a range of unmet supportive care needs. It was evident that living with kidney failure and receiving haemodialysis impacted a person's sense of self, introduced practical needs and other complex needs which were not being addressed in existing services. This review has highlighted important implications for clinical practice and future research directions.

A comparison of health‐related quality of life in chronic intestinal failure and end‐stage kidney disease: A cross‐sectional study

“…[37][38][39][40] Lastly, people undergoing both treatments may experience emotional and psychological stress due to their medical condition and treatment. 41,42 It has previously been established that both people with CIF and receiving HD have significantly poorer HRQOL compared with the general population. 11,43,44 To our knowledge, this is the first study to compare the HRQOL in people with CIF to that of another and more common nonmalignant type of organ failure.…”

“…Anemia and metabolic bone disease are known complications of both IF and CKD, but the underlying pathophysiologic mechanisms differ 37–40 . Lastly, people undergoing both treatments may experience emotional and psychological stress due to their medical condition and treatment 41,42 …”

Mapping the empirical evidence on patient involvement interventions in patients with end-stage kidney disease making end-of-life care decisions: a scoping review protocol

“…A preliminary search was conducted of MED-LINE, JBI Evidence Synthesis, the Cochrane Database of Systematic Reviews, and PROSPERO. The search revealed one published scoping review, 18 one scoping review protocol, 19 one systematic review, 20 one systematic realist review, 1 and five protocols of ongoing systematic reviews [21][22][23][24][25] with a similar topic to this scoping review. However, these studies differ from the proposed scoping review with regard to design, study population, major outcomes, or other study aspects:…”

“…It differs from our review by including only qualitative studies and excluding studies about EoLC in the terminal phase of the illness. The protocol by Mckie et al 24 aims to investigate the unmet supportive care needs of patients with kidney disease, focusing on the differences between age groups. Both Frandsen et al 23 and Mckie et al 24 include patients at all stages of kidney disease (stages 1 through 5).…”

“…The protocol by Mckie et al 24 aims to investigate the unmet supportive care needs of patients with kidney disease, focusing on the differences between age groups. Both Frandsen et al 23 and Mckie et al 24 include patients at all stages of kidney disease (stages 1 through 5). The protocol by Ruanta et al 25 aims to examine the experiences of decision-making within all treatment options for patients with ESKD, their caregivers, and health professionals, but not regarding EoLC.…”